Brief: Neuren Pharmaceuticals Says Acadia Pharmaceuticals Received U.S. FDA Approval Of Daybue
12/03/2023 23:28
March 13 (Reuters) - Neuren Pharmaceuticals Ltd
NEU.AX :
* ACADIA PHARMACEUTICALS RECEIVED US FOOD AND DRUG
ADMINISTRATION
APPROVAL OF DAYBUE (TROFINETIDE)
Source text for Eikon: ID:nASXPQX5f
Further company coverage: NEU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neuren Pharmaceuticals
See all newsAustralia's Neuren set for weekly gain on FDA nod, drug forecast upgrade
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union